A Prospective, Randomized Trial of Prednisone and Cyclophosphamide in the Treatment of Patients with Factor VIII Autoantibodies

David Green; Alfred W Rademaker; Ernest Briët

doi:10.1055/s-0038-1649664

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1993; 70(05): 753-757
DOI: 10.1055/s-0038-1649664

Clinical Studies

Schattauer GmbH Stuttgart

A Prospective, Randomized Trial of Prednisone and Cyclophosphamide in the Treatment of Patients with Factor VIII Autoantibodies

David Green

The Division of Hematology/Oncology, Department of Medicine, and Cancer Biometry Division, Northwestern University Medical School, Chicago, Illinois, and the Department of Hematology, University of Leiden, Leiden, The Netherlands

,

Alfred W Rademaker

The Division of Hematology/Oncology, Department of Medicine, and Cancer Biometry Division, Northwestern University Medical School, Chicago, Illinois, and the Department of Hematology, University of Leiden, Leiden, The Netherlands

,

Ernest Briët

The Division of Hematology/Oncology, Department of Medicine, and Cancer Biometry Division, Northwestern University Medical School, Chicago, Illinois, and the Department of Hematology, University of Leiden, Leiden, The Netherlands

› Author Affiliations

Abstract

PDF Download

Summary

Thirty-one non-hemophilic patients with acquired antibodies to factor VIII were entered into a prospective, randomized, multi- institutional trial to determine the safety and efficacy of prednisone (P), cyclophosphamide ©, or the combination in the treatment of this disorder. Patients were eligible if they had antibody demonstrated by the Bethesda assay, had not received these agents previously, and gave informed consent. All patients were treated initially with P, 1 mg/kg, for 3 weeks. If the antibody persisted and there was no rise in factor VIII activity, patients were randomized to either continue P for an additional 6 weeks; taper P and begin C, 2 mg per kg; or continue P and add C. Antibody disappeared in 10 during the initial P therapy, and in three of four others randomized to continue on P; one patient was discontinued because of an herpetic infection. Antibody disappeared in three of six patients treated with C alone, and five of ten given C and P. The titer of antibody was significantly lower in responders than in non-responders (p = 0.003), but seven patients with titers of more than five Bethesda units had complete remissions. There was no difference in antibody titers between those responding to P and those responding to C. We conclude that all patients with acquired antibodies to factor VIII should receive initial management with P, and that C is effective as second-line therapy for many of those who are steroid-resistant.

PDF (1237 kb)

References

References
1 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemostas 1981; 45: 200-203
2 Northwestern Memorial Hospital Ethics Workshop, Northwestern Medical Center. 09/1989
3 Lottenberg R, Kentro TB, Kitchens CS. Acquired hemophilia: a natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987; 147: 1077-1081
4 Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired factor VIII :C inhibitors. Br J Haematol 1981; 48: 635-642
5 Herbst KD, Rapaport SI, Kenoyer DG, Stanton W, Feinstein DI. Syndrome of an acquired inhibitor of factor VIII responsive to cyclophosphamide and prednisone. Ann Intern Med 1981; 95: 575-578
6 Lian ECY, Larcada AF, Chiu AYZ. Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989; 110: 774-778
7 Kasper CK, Aledort LM, Counts RB. et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872
8 Kessler CM. (ed) Acquired factor VIII inhibitors in the nonhemophiliac: historical perspectives, current therapies, and future approaches. Am J Med 1991; 91 (05) A 1S-48S
9 Lusher JM. Perspectives on the use of factor IX complex concentrates in the treatment of bleeding in persons with acquired factor VIII inhibition. Am J Med 1991; 91 (05) A 30S-34S
10 Sultan Y, Kazatchkine MD, Nydegger U, Rossi F, Dietrich G, Algiman M. Intravenous immunoglobulin in the treatment of spontaneously acquired F VIII :C inhibitors. Am J Med 1991; 91 (05) A 35S-39S
11 Austin HA, Klippel JH, Balow JE. et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619
12 Euler HH, Teske E, Schwab UM, Harten P, Schroeder JO. Treatment-free remission following plasmapheresis and subsequent pulse cyclophosphamide in severe SLE. Am Coll Rheumat 56th Annu Meeting. S35 1992. (abstr).
13 Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener’S granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-410
14 Euler HH, Loffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Dermatol 1987; 123: 1205-10
15 Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 1971; 37: 381-387
16 Waltke EA, Jacobs SC, Hussey CV, Lawson RK. Massive hematuria due to acquired factor VIII inhibitor: treatment with cyclophosphamide. J Urol 1981; 18: 601-603
17 Pfliegler G, Bode Z, Harsfalvi J, Flora-Nagy M, Sari B, Pesze K, Rak K. Cyclosporine treatment of a woman with acquired hemophilia due to FVIII:C inhibitor. Postgrad Med J 1989; 65: 400-402